Genome Editing for a Better Life
We are developing ex vivo and in vivo gene-editing therapies for a range of diseases. Our lead program, ET-01 for patients with b-thalassemia, expects to enter clinic in 2019, offering the potential for a novel, safe and tolerable therapy for patients without HLA-matching donors through autologous hematopoietic stem cell transplant.
Our lead program, ET-01, is a CRISPR-based gene-editing therapy being developed for patients with b-thalassemia, through raising the level of fetal hemoglobin. Prior clinical observation has suggested that in patients with b-thalassemia, increased production of fetal hemoglobin can compensate for the defective production of the b-hemoglobin molecules.
We are currently building a GMP manufacturing facility in Guangzhou, China, and expect to advance ET-01 to clinic in 2019.
ET-02 is a CRISPR-based gene-editing therapy to produce Universal Chimeric Antigen Receptor T cell
Therapy (U-CAR-T). One of the most exciting treatment breakthroughs in recent years, autologous
CAR-T therapies have been approved to treat multiple cancers. By knocking out selected genes
involved in immunogenicity, it is possible to produce U-CAR-T from healthy donors as an
“off-the-shelf” product to treat cancer patients, potentially resulting in readily
availability, more consistent quality and lower cost.
In vivo Therapeutics
We are developing novel gene-editing technology-based therapies to treat selected diseases. To that end,
we have also been developing in vivo drug delivery platforms, including virus-based systems and lipid nanoparticles.
Building No.22, Kexueyuan Road, Changping Distriction, Beijing, China
Building 10, No.6, Nanjianger Road, Zhujiang Street, Nansha Distriction, Guangzhou, China
EDIGENE BIOTECHNOLOGY USA INC.
245 FIRST STREET, RIVERVIEW II, 18TH FLOORCAMBRIDGE, MA 02142 USA
京ICP备15043562号-1 博雅辑因(北京)生物科技有限公司版权所有 © 2015-2018
Edigene Inc. all rights reserved. 2015-2018